AP2015008955A0 - A novel formulation of indomethacin - Google Patents

A novel formulation of indomethacin

Info

Publication number
AP2015008955A0
AP2015008955A0 AP2015008955A AP2015008955A AP2015008955A0 AP 2015008955 A0 AP2015008955 A0 AP 2015008955A0 AP 2015008955 A AP2015008955 A AP 2015008955A AP 2015008955 A AP2015008955 A AP 2015008955A AP 2015008955 A0 AP2015008955 A0 AP 2015008955A0
Authority
AP
ARIPO
Prior art keywords
indomethacin
novel formulation
formulation
novel
Prior art date
Application number
AP2015008955A
Other languages
English (en)
Inventor
Aaron Dodd
Marck Norret
Adrian Russell
Original Assignee
Icuetica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43010611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008955(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2009901745A external-priority patent/AU2009901745A0/en
Application filed by Icuetica Pty Ltd filed Critical Icuetica Pty Ltd
Publication of AP2015008955A0 publication Critical patent/AP2015008955A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AP2015008955A 2009-04-24 2010-04-23 A novel formulation of indomethacin AP2015008955A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17229509P 2009-04-24 2009-04-24
AU2009901745A AU2009901745A0 (en) 2009-04-24 A Novel Formulation of Indomethacin
PCT/AU2010/000472 WO2010121328A1 (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin

Publications (1)

Publication Number Publication Date
AP2015008955A0 true AP2015008955A0 (en) 2015-12-31

Family

ID=43010611

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2011005992A AP3628A (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin
AP2015008955A AP2015008955A0 (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AP2011005992A AP3628A (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin

Country Status (22)

Country Link
US (8) US20120135048A1 (zh)
EP (1) EP2421513B1 (zh)
JP (3) JP6027890B2 (zh)
KR (3) KR20120101285A (zh)
CN (2) CN102438594A (zh)
AP (2) AP3628A (zh)
AU (1) AU2010239081C1 (zh)
BR (1) BRPI1014275B8 (zh)
CA (1) CA2759125C (zh)
CO (1) CO6470807A2 (zh)
DK (1) DK2421513T3 (zh)
EA (1) EA201171286A1 (zh)
IL (2) IL215872A (zh)
MA (1) MA33296B1 (zh)
MX (1) MX351930B (zh)
MY (1) MY159208A (zh)
NZ (3) NZ710384A (zh)
SG (2) SG10201401695VA (zh)
TN (1) TN2011000544A1 (zh)
UA (1) UA106231C2 (zh)
WO (1) WO2010121328A1 (zh)
ZA (1) ZA201108646B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2759104C (en) * 2009-04-24 2019-01-29 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
KR20120088546A (ko) * 2009-04-24 2012-08-08 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
DK2421513T3 (en) * 2009-04-24 2018-03-26 Iceutica Pty Ltd UNKNOWN FORMULATION WITH INDOMETHACIN
WO2012027366A2 (en) 2010-08-23 2012-03-01 President And Fellows Of Harvard College Acoustic waves in microfluidics
CN103249405A (zh) * 2010-08-23 2013-08-14 哈佛学院院长等 用于药物递送和其他应用的颗粒
JP5909796B2 (ja) * 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
AU2014232508C1 (en) * 2013-03-15 2023-01-19 Sun Pharmaceutical Industries Limited Abiraterone acetate formulation
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US10258987B2 (en) 2014-06-26 2019-04-16 President And Fellows Of Harvard College Fluid infection using acoustic waves
DK3341116T3 (da) 2015-08-27 2022-05-02 Harvard College Sorteringsfremgangsmåde under anvendelse af akustiske bølger
CN113995755A (zh) 2016-02-04 2022-02-01 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11701658B2 (en) 2019-08-09 2023-07-18 President And Fellows Of Harvard College Systems and methods for microfluidic particle selection, encapsulation, and injection using surface acoustic waves
TR202017034A2 (tr) * 2020-10-26 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172546A (en) 1961-05-19 1965-03-09 Union Carbide Corp Size reduction of biological substances
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4200631A (en) * 1975-12-17 1980-04-29 Richter Gedeon Vegyeszeti Gyar Rt. Treating mammalian subject sensitive to indomethacin ulcerogenisis
IT1082518B (it) 1977-01-25 1985-05-21 Fiat Spa Specchio a cristallo liquido da impiegare particolarmente come retrovisore per veicoli
NL175882C (nl) * 1977-03-28 Procter & Gamble Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
IL112746A (en) 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
AU750125B2 (en) 1997-08-27 2002-07-11 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
JPH11130698A (ja) * 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
EP1066825A1 (en) 1999-06-17 2001-01-10 The Procter & Gamble Company An anti-microbial body care product
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4541647B2 (ja) 2000-11-20 2010-09-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
CA2436570A1 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
CA2451161A1 (en) 2001-06-22 2003-01-03 Elan Pharma International, Ltd. Method for high through put screening using a small scale mill or microfluidics
JP2003066613A (ja) 2001-08-22 2003-03-05 Columbia Music Entertainment Inc スタンパの製造方法
EP1443912B1 (en) 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US6825161B2 (en) 2002-04-26 2004-11-30 Salvona Llc Multi component controlled delivery system for soap bars
WO2004019937A1 (en) 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
AU2003266940B2 (en) 2002-09-30 2007-02-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
WO2004058216A2 (en) 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
AU2003230189A1 (en) 2003-01-29 2004-08-23 Nitin Bhalachandra Dharmadhikari Oral controlled release pharmaceutical composition containing metaxalone as active agent
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2004100857A2 (en) * 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
DE60309356T2 (de) * 2003-06-27 2007-08-30 Bioprogress S.P.A. Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
CA2534924A1 (en) 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
ATE362395T1 (de) 2003-10-01 2007-06-15 Debio Rech Pharma Sa Vorrichtung und verfahren zur herstellung von partikeln
EP1686962B9 (en) 2003-11-05 2012-10-03 Elan Pharma International Limited Nanoparticulate compositions having a peptide as a surface stabilizer
US20050276844A1 (en) 2004-03-08 2005-12-15 Spiridon Spireas Bioavailable compositions of metaxalone and processes for producing the same
CN101005828B (zh) 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
WO2006009419A1 (es) 2004-07-19 2006-01-26 Luis Cordova Boone Neumáticos con doble banda de rodamiento
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (en) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Pharmaceutical dosage form comprising meloxicam
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US20090028948A1 (en) 2004-12-31 2009-01-29 Iceutica Pty Ltd Nanoparticle composition and methods of synthesis thereof
CN101212954A (zh) 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US20080292584A1 (en) 2005-10-14 2008-11-27 Mutual Pharmaceutical Company, Inc. Metaxalone products, method of manufacture, and method of use
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
DE602006009710D1 (de) 2005-12-15 2009-11-19 Acusphere Inc Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur parenteralen verabreichung
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007074477A2 (en) 2005-12-29 2007-07-05 Dabur Pharma Limited Metaxalone polymorphs
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
KR20090023729A (ko) 2006-06-23 2009-03-05 엘란 파마 인터내셔널 리미티드 나노입자형 멜록시캄 및 조절 방출형 하이드로코돈을 포함하는 조성물
TWI645862B (zh) 2006-06-30 2019-01-01 艾修提卡股份有限公司 包含奈米微粒形式生物活性化合物之劑型形式
CA2653384C (en) * 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CN100386312C (zh) 2006-07-18 2008-05-07 上海世景国际贸易有限公司 2，4-二氨基苯磺酸及其盐的合成方法
WO2008013416A1 (en) 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
AP3774A (en) 2009-04-24 2016-08-31 Iceutica Pty Ltd A novel formulation of diclofenac
SG175309A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
NZ595902A (en) 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
CA2759104C (en) 2009-04-24 2019-01-29 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
DK2421513T3 (en) 2009-04-24 2018-03-26 Iceutica Pty Ltd UNKNOWN FORMULATION WITH INDOMETHACIN
CN103877030A (zh) 2009-04-24 2014-06-25 伊休蒂卡有限公司 甲氧萘普酸的新剂型
CN102438627A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 美洛昔康的新剂型
KR20120088546A (ko) 2009-04-24 2012-08-08 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
AU2010239082B2 (en) 2009-04-24 2014-10-16 Iceutica Pty Ltd A novel formulation of metaxalone
JP2011005735A (ja) 2009-06-25 2011-01-13 Olympus Corp 画像記録装置及び画像記録装置の初期化制御方法

Also Published As

Publication number Publication date
CO6470807A2 (es) 2012-06-29
US20140256781A1 (en) 2014-09-11
EP2421513A4 (en) 2012-12-05
US20140255494A1 (en) 2014-09-11
IL215872A (en) 2016-08-31
BRPI1014275B1 (pt) 2020-09-15
BRPI1014275A2 (pt) 2016-10-18
SG175315A1 (en) 2011-11-28
KR101743847B1 (ko) 2017-06-05
US8992982B2 (en) 2015-03-31
KR20150030782A (ko) 2015-03-20
MY159208A (en) 2016-12-30
US20120135048A1 (en) 2012-05-31
IL247034A (en) 2017-07-31
MX351930B (es) 2017-11-03
KR20120101285A (ko) 2012-09-13
US20180117008A1 (en) 2018-05-03
CA2759125A1 (en) 2010-10-28
EP2421513B1 (en) 2017-12-13
UA106231C2 (uk) 2014-08-11
EP2421513A1 (en) 2012-02-29
JP2015051995A (ja) 2015-03-19
SG10201401695VA (en) 2014-08-28
NZ595986A (en) 2014-04-30
JP6027890B2 (ja) 2016-11-16
US10172828B2 (en) 2019-01-08
DK2421513T3 (en) 2018-03-26
CN102438594A (zh) 2012-05-02
AU2010239081C1 (en) 2014-11-06
US20160022637A1 (en) 2016-01-28
US20170095448A1 (en) 2017-04-06
IL215872A0 (en) 2012-01-31
US8734847B2 (en) 2014-05-27
JP6043329B2 (ja) 2016-12-14
EA201171286A1 (ru) 2012-05-30
WO2010121328A1 (en) 2010-10-28
NZ620879A (en) 2015-08-28
US20140194487A1 (en) 2014-07-10
US9849111B2 (en) 2017-12-26
US20130243854A1 (en) 2013-09-19
AU2010239081A1 (en) 2011-11-10
KR20140077945A (ko) 2014-06-24
CN103932988A (zh) 2014-07-23
NZ710384A (en) 2017-03-31
US9522135B2 (en) 2016-12-20
US9095496B2 (en) 2015-08-04
AP2011005992A0 (en) 2011-12-31
JP2012524724A (ja) 2012-10-18
TN2011000544A1 (en) 2013-05-24
CA2759125C (en) 2017-08-15
US9089471B2 (en) 2015-07-28
JP6239709B2 (ja) 2017-11-29
ZA201108646B (en) 2013-01-30
MA33296B1 (fr) 2012-05-02
AP3628A (en) 2016-03-08
BRPI1014275B8 (pt) 2021-05-25
AU2010239081B2 (en) 2014-06-12
JP2017019848A (ja) 2017-01-26
MX2011011226A (es) 2012-02-08

Similar Documents

Publication Publication Date Title
AP3628A (en) A novel formulation of indomethacin
HK1231383A1 (zh) 雙氯芬酸的新劑型
EP2339918A4 (en) PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE
ZA201108648B (en) A novel formulation of naproxen
AP3659A (en) A novel formulation of meloxicam
GB0907003D0 (en) Formulation
HK1142219A2 (en) Tripod
EP2413905A4 (en) COMPOSITION
HK1142226A2 (en) Tripod
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
IL257014A (en) A novel formulation of meloxicam
GB0911213D0 (en) Formulation
AU2009901745A0 (en) A Novel Formulation of Indomethacin
GB0915468D0 (en) Get me out of here
GB0904499D0 (en) A set of parts
GB0901420D0 (en) Formula 1-2050
GB0906291D0 (en) Formulation
GB0907410D0 (en) Formulation
GB0902472D0 (en) Formulation
GB0905280D0 (en) Novel uses of VEGFxxxb
GB0903773D0 (en) Works of art
GB0919237D0 (en) Improvements of a device
GB0902525D0 (en) Pharmacophores